Pegfilgrastim

Details

Files

Generic Name:

Pegfilgrastim

Project Status:

Complete

Therapeutic Area:

Neutropenia

Manufacturer:

Amgen Canada Inc.

Brand Name:

Neulasta

Project Line:

Reimbursement Review

Project Number:

SR0009-000

Submission Type:

Initial

Indications:

Neutropenia

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

October 27, 2004

Recommendation:

List for patients with non-myeloid cancer who are receiving regimens with curative intent who are at high risk of developing prolonged neutropenia.

Last Updated : March 29, 2004